News

November 6, 2020

Kannalife, Inc. Rebrands as Neuropathix, Inc. and Unveils New Ticker Symbol

September 17, 2020

Kannalife, Inc. Appoints Dr. Tage Honoré as Chairman of the Company’s Board of Advisors

June 30, 2020

Kannalife, Inc. Bolsters IP Portfolio with Multiple Patents Issued in 12 Key European Territories

June 2, 2020

Kannalife, Inc. Appoints Terrence O. Tormey to the Company’s Board of Advisors

April 14, 2020

Kannalife, Inc. Announces Results from Comparative UVB-Radiation Study on Atopidine™ Versus CBD

April 1, 2020

Kannalife, Inc. Receives Notice of Allowance from USPTO for Trademark of Atopidine™

February 18, 2020

Kannalife Bolsters its Global Intellectual Property Portfolio with New Chinese-Issued Patent

February 11, 2020

Kannalife, Inc. Announces Completion of NIH-NIDA Phase 1 Grant and Results from Lewis Katz School of Medicine at Temple University for the Potential Use of KLS-13019 in the Treatment of CIPN

January 28, 2020

Kannalife, Inc. CEO Recaps 2019 Advances and Potential Ahead

January 22, 2020

Kannalife, Inc. Issues Update on Intellectual Property and Patent Estate

January 14, 2020

Kannalife, Inc. Further Elucidates Mechanism of Action Behind KLS-13019, the Company’s Leading Drug Candidate for the Potential Treatment of Neuropathic Pain

January 7, 2020

Kannalife Secures New INCI Name for its Prospective Anti-Inflammatory and Antioxidant Ingredient Atopidine™

December 18, 2019

CBD: Perils, Promise and Development for Neuropathic Pain

December 11, 2019

Kannalife, Inc. Announces Filing of U.S. Patent 62/934,861 – Functionalized 1, 3 Benzene Diols and Their Method of Use for the Treatment of Radiation Dermatitis and Other Skin Disorders

December 9, 2019

Kannalife, Inc. Commences Trading on OTCQB Under Ticker Symbol “KLFE”

June 27, 2019

Kannalife, Inc. to Present Breakthrough CIPN Study Findings on the Comparison of KLS-13019 to CBD at 29th Annual International Cannabinoid Research Society Conference

May 21, 2019

Kannalife Inc. Publishes New Research on Chemotherapy-Induced Peripheral Neuropathy

March 24, 2019

Kannalife Spokesman former NFL kicker Nick Lowery on Head Injuries, CBD Treatment

February 5, 2019

Kannalife Spokesman Nick Lowery Wins 2018 CNBC Stock Draft

January 16, 2019

Kannalife Announces Completion of Name Change, Ticker Symbol Change

Get the Latest in Neuropathix News

Subscribe